Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835653 | 0.86 | MEN1 (0.48) | EGFRCA1HDAC3HDAC4HDAC1 | |
| SCHEMBL30278664 | 0.86 | MEN1 (0.48) | EGFRCA1HDAC3HDAC4HDAC1 | |
| SCHEMBL13524340 | 0.85 | PTPN11 (0.53) | EGFRAURKBRAF1KDRMAP2K2 | |
| SCHEMBL10845090 | 0.82 | AURKB (0.53) | EGFRAURKBRAF1KDRMAP2K2 | |
| SCHEMBL14679395 | 0.82 | HPGD (0.59) | EGFRAURKBRAF1KDRMAP2K2 | |
| SCHEMBL15584697 | 0.81 | MALT1 (0.46) | CA1CA2IDH1PTPN11 | |
| SCHEMBL2472278 | 0.81 | MAPK1 (0.57) | EGFRAURKBRAF1KDRMAP2K2 | |
| SCHEMBL15145868 | 0.81 | EGFR (0.68) | EGFRAURKBRAF1KDRMAP2K2 | |
| SCHEMBL12464423 | 0.81 | AURKB (0.54) | EGFRAURKBRAF1KDRMAP2K2 | |
| SCHEMBL4478423 | 0.80 | HDAC3 (0.51) | EGFRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498353-B2 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498353-B2 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498353-B2 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| CN-101203498-A | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS INC (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1883633-A2 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007027230-A2 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027230-A2 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060247287-A1 | Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247287-A1 | Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses | HAVCR2, HCCS, AADAC | EGFR 3333/4885AURKB 2951/4885RAF1 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.